- Home
- VRAX vs CDT Comparison
VRAX vs CDT Comparison
Compare VRAX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- CDT
- Stock Information
- Founded
- VRAX 2013
- CDT 2019
- Country
- VRAX United Kingdom
- CDT United States
- Employees
- VRAX N/A
- CDT N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- CDT Health Care
- Exchange
- VRAX Nasdaq
- CDT Nasdaq
- Market Cap
- VRAX 4.4M
- CDT 5.2M
- IPO Year
- VRAX 2022
- CDT N/A
- Fundamental
- Price
- VRAX $0.75
- CDT $1.57
- Analyst Decision
- VRAX Strong Buy
- CDT
- Analyst Count
- VRAX 1
- CDT 0
- Target Price
- VRAX $3.00
- CDT N/A
- AVG Volume (30 Days)
- VRAX 132.3K
- CDT 95.0K
- Earning Date
- VRAX 01-01-0001
- CDT 08-26-2025
- Dividend Yield
- VRAX N/A
- CDT N/A
- EPS Growth
- VRAX N/A
- CDT N/A
- EPS
- VRAX N/A
- CDT N/A
- Revenue
- VRAX $6,331.00
- CDT N/A
- Revenue This Year
- VRAX $217,274.83
- CDT N/A
- Revenue Next Year
- VRAX N/A
- CDT N/A
- P/E Ratio
- VRAX N/A
- CDT N/A
- Revenue Growth
- VRAX N/A
- CDT N/A
- 52 Week Low
- VRAX $0.72
- CDT $1.61
- 52 Week High
- VRAX $9.00
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- VRAX 38.90
- CDT 30.13
- Support Level
- VRAX $0.72
- CDT $1.61
- Resistance Level
- VRAX $0.80
- CDT $1.85
- Average True Range (ATR)
- VRAX 0.07
- CDT 0.10
- MACD
- VRAX -0.01
- CDT 0.02
- Stochastic Oscillator
- VRAX 10.07
- CDT 13.79
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.